Home / Community / News


08/14/2017 - 8:43am

A novel redirection of CRISPR/Cas9 technology addresses toxic RNA, rather than the genome, as a potential therapy for DM1 and DM2.

08/11/2017 - 5:19pm

To develop new therapies for patients living with myotonic dystrophy (DM), specific “infrastructure” needs must be addressed—this infrastructure makes clinical trials feasible. It is essential to understand how a disease manifests and progresses in a cohort of patients that is sufficiently large and representative to provide confidence in the findings. This understanding, in turn, allows the design and validation of outcome measures that are sufficiently sensitive, reliable, valid and responsive to show whether a candidate therapy is effective or not.

08/11/2017 - 4:44pm

Understanding cardiac and other DM risk factors and planning for the known complications of DM that may affect you can help protect and maintain your quality of life and that of your loved ones.

08/07/2017 - 11:18am

A new study points to the timing of MBNL-dependent RNA processing defects as a major factor in the pathogenesis of CDM.

08/07/2017 - 10:53am

Although fatigue represents a substantial burden in DM1, tools must be validated to assess its diverse contributing factors in order to develop clinical trial endpoints and effective therapies.


© Myotonic Dystrophy Foundation. All rights reserved.